Pipeline
: Scientific Presentations

Scientific Presentations

Efficacy and Safety of TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia in the RELIEF Study: Positive Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Trial

Efficacy and Safety of TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia in the RELIEF Study: Positive Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Trial

Presented at the American Society of Clinical Psychopharmacology (ASCP) 2021 Annual Meeting Virtual Conference, June 01-04, 2021

Gregory Sullivan1, Mary Kelley1, Annabelle Iserson1, Perry Peters1, Ashild Peters1, Candace Flint1, Judy Gendreau2, Herb Harris1, Ben Vaughn3, and Seth Lederman1

1Tonix Pharmaceuticals, Inc., New York, NY 2Gendreau Consulting LLC, Poway, CA 3Rho, Inc, Chapel Hill, NC

Uploaded: Jun 3, 2021
Type: Pdf
Effect of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) on PTSD Sleep-Dependent Emotional Memory Processing: Retrospective Analysis of Phase 2 and 3 Trial Results in Military-Related and Civilian PTSD

Effect of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) on PTSD Sleep-Dependent Emotional Memory Processing: Retrospective Analysis of Phase 2 and 3 Trial Results in Military-Related and Civilian PTSD

Presented at the American Society of Clinical Psychopharmacology (ASCP) 2021 Annual Meeting Virtual Conference, June 01-04, 2021

Megan Parmenter1, Annabelle Iserson2, Jean Engels3, Bernard Gorman1, Seth Lederman2, and Gregory Sullivan2

1Adelphi University, 2Tonix Pharmaceuticals, Inc. 3Engels Statistical Consulting LLC

Uploaded: Jun 3, 2021
Type: Pdf
Intranasal (IN) Oxytocin Relieves Pain and Depressive Behavior in a Rodent Model of Mild Traumatic Brain Injury (TBI)

Intranasal (IN) Oxytocin Relieves Pain and Depressive Behavior in a Rodent Model of Mild Traumatic Brain Injury (TBI)

Presented at the American Academy of Neurology’s Sports Concussion Conference held virtually July 31 – August 1, 2020

Shashidhar H Kori, David Yeomans, Michael Klukinov

Uploaded: Aug 4, 2020
Type: Pdf
Stabilized recombinant trefoil factor 2 (TFF2-CTP) enhances anti-tumor activity of PD-1 blockade in mouse models of colorectal cancer

Stabilized recombinant trefoil factor 2 (TFF2-CTP) enhances anti-tumor activity of PD-1 blockade in mouse models of colorectal cancer

Presented at the American Association of Cancer Research (AACR) Virtual Annual Meeting II being held June 22-24, 2020

Woosook Kim, Na Fu, Phaneendra Duddempudi, Zinaida Dubeykovskaya, Steven Almo, Chandan Guha, Seth Lederman, Timothy Wang

Uploaded: Jun 22, 2020
Type: Pdf
Synthetic Chimeric Horsepox Virus (scHPXV) Vaccination Protects Macaques from Monkeypox*

Synthetic Chimeric Horsepox Virus (scHPXV) Vaccination Protects Macaques from Monkeypox*

Presented at the American Society of Microbiology (ASM) BioThreats Conference in Arlington, VA on January 29, 2020 Poster Session #2 - 4:15 pm.

Ryan Noyce, Landon Westfall, Siobhan Fogarty, Karen Gilbert, Onesmo Mpanju, Helen Stillwell, Jose Esparza, Fusataka Koide, David Evans, and Seth Lederman

Uploaded: Jan 29, 2020
Type: Pdf
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia (FM): Evidence for a Broad Spectrum of Activity on the FM Syndrome

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia (FM): Evidence for a Broad Spectrum of Activity on the FM Syndrome

Presented by Dr. Gregory Sullivan at the American College of Rheumatology in Atlanta, GA on November 10, 2019

Gregory Sullivan, R. Michael Gendreau, Judith Gendreau, Ashild Peters, Perry Peters, and Seth Lederman

Uploaded: Nov 20, 2019
Type: Pdf
Steady-State Pharmacokinetic Properties of a Sublingual Formulation of Cyclobenzaprine (CBP) HCl (TNX-102 SL*): Comparison to Simulations of Oral Immediate Release CBP

Steady-State Pharmacokinetic Properties of a Sublingual Formulation of Cyclobenzaprine (CBP) HCl (TNX-102 SL*): Comparison to Simulations of Oral Immediate Release CBP

Presented at the American Society of Clinical Psychopharmacology in Scottsdale, AZ on May 29, 2019 Poster Session I – Poster ID W29, 11:15 AM – 1 PM EDT, Palomino

Gregory Sullivan, Regina Kiu, Helen Stillwell, Bernd Meibohm, and Seth Lederman

Uploaded: May 29, 2019
Type: Pdf
Time Since Trauma in PTSD: Phase 3 Multi-Center, Double-Blind, Placebo-Controlled Trial of TNX-102 SL*,a Sublingual Formulation of Cyclobenzaprine, in Military-Related PTSD (Study TNX-CY-P301)

Time Since Trauma in PTSD: Phase 3 Multi-Center, Double-Blind, Placebo-Controlled Trial of TNX-102 SL*,a Sublingual Formulation of Cyclobenzaprine, in Military-Related PTSD (Study TNX-CY-P301)

Presented at CNS Summit in Boca Raton, FL November 1-4, 2018; Poster 8A, Friday Nov. 2, 5:00-7:00 PM EDT, Reception and Poster Session, and abstract published in Innovations in Clinical Neuroscience, November-December 2018;15(11-12, suppl):S10.

Gregory Sullivan, MD, R Michael Gendreau, MD, PhD, Judy Gendreau, MD, Ashild Peters, RN, Perry Peters, Jean Engels, MS, Seth Lederman, MD

Uploaded: Nov 6, 2018
Type: Pdf
Differential Treatment Effects of a Sublingual Formulation of Cyclobenzaprine (TNX-102 SL*) on Dissociative Symptoms of Derealization and Depersonalization in a Military-Related PTSD

Differential Treatment Effects of a Sublingual Formulation of Cyclobenzaprine (TNX-102 SL*) on Dissociative Symptoms of Derealization and Depersonalization in a Military-Related PTSD

Presented at CNS Summit in Boca Raton, FL November 1-4, 2018; Poster 8A, Friday Nov. 2, 5:00-7:00 PM EDT, Reception and Poster Session, and abstract published in Innovations in Clinical Neuroscience, November-December 2018;15(11-12, suppl):S9.

Gregory M. Sullivan, Kimmons Wilson, R. Michael Gendreau, Judy Gendreau, Ashild Peters, Perry Peters, Amy Forst, Jean Engels, Seth Lederman

Uploaded: Nov 6, 2018
Type: Pdf
Effect of Time Since Trauma on Response to TNX-102 SL* (Cyclobenzaprine Sublingual Tablets) in Military-Related PTSD: Results of Two Double-Blind Randomized Placebo-Controlled Studies

Effect of Time Since Trauma on Response to TNX-102 SL* (Cyclobenzaprine Sublingual Tablets) in Military-Related PTSD: Results of Two Double-Blind Randomized Placebo-Controlled Studies

Presented at the 2018 Military Health System Research Symposium in Kissimmee, FL August 20 – 23

Poster Discussion Session: Innovations in PTSD Treatment Research

Gregory Sullivan, R Michael Gendreau, Judy Gendreau, Ashild Peters, Perry Peters, Amy Forst, Jean Engels, Seth Lederman

Uploaded: Aug 21, 2018
Type: Pdf
1 | 2 | 3 | 4 | 5 Next >>